RICARDO ROQUE CIBOTTI
Pilots at Amy Ln, Bethesda, MD
License number
Maryland A4430403
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
7102 Amy Ln, Bethesda, MD 20817
Professional information
Interferon Alpha-Induced Pharmacodynamic Markers
US Patent:
2010014, Jun 10, 2010
Filed:
Dec 6, 2007
Appl. No.:
12/517333
Inventors:
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Washington DC, US
Peter Kiener - Potomac MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Washington DC, US
Peter Kiener - Potomac MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
A61K 39/395, C12Q 1/68
US Classification:
4241581, 435 6
Abstract:
The present invention encompasses type-1 IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.
Interferon Alpha-Induced Pharmacodynamic Markers
US Patent:
2011028, Nov 24, 2011
Filed:
Jun 19, 2009
Appl. No.:
12/999626
Inventors:
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Boston MA, US
Peter Kiener - Potomac MD, US
Barbara White - Finksburg MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Boston MA, US
Peter Kiener - Potomac MD, US
Barbara White - Finksburg MD, US
Assignee:
Medlmmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395, C40B 30/04, A61P 29/00, A61P 17/06, A61P 19/02, G01N 33/53, C12Q 1/02
US Classification:
4241581, 436501, 506 9, 435 29
Abstract:
The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognoses to patients having IFNα-induced disorders.
Interferon Alpha-Induced Pharmacodynamic Markers
US Patent:
2010026, Oct 14, 2010
Filed:
May 5, 2008
Appl. No.:
12/598526
Inventors:
Yihong Yao - Boyds MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Washington DC, US
Peter Kiener - Potomac MD, US
Bahija Jallal - Potomac MD, US
Ricardo Cibotti - Bethesda MD, US
Anthony Coyle - Washington DC, US
Peter Kiener - Potomac MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.
Anti-Ifnar1 Antibodies With Reduced Fc Ligand Affinity
US Patent:
2011005, Mar 10, 2011
Filed:
Feb 6, 2009
Appl. No.:
12/866579
Inventors:
Anthony Coyle - Boston MA, US
Peter Kiener - Potomac MD, US
Herren Wu - Boyds MD, US
Ricardo Cibotti - Bethesda MD, US
Peter Kiener - Potomac MD, US
Herren Wu - Boyds MD, US
Ricardo Cibotti - Bethesda MD, US
Assignee:
Medimmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395, C07K 16/28, C07H 21/00, C12N 5/10, A61P 37/02, A61P 37/06
US Classification:
4241331, 5303873, 536 2353, 435325
Abstract:
The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.